TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36412106

Group type: EXPERIMENTAL
Intervention: Message emphasising the effect of alcohol on the immune system
Number of subjects: 953

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Message emphasising the effect of alcohol on mental health
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Message emphasising the effect of alcohol on physical health
Number of subjects: 953
Study: 32004998

Group type: EXPERIMENTAL
Intervention: 250 mg d-cycloserine (DCS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 35651892

Group type: EXPERIMENTAL
Intervention: Telerehabilitation group (TeleGr)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (CGr)
Number of subjects: 34
Study: 34792483

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Staged PCI
Number of subjects: 151
Study: 33340878

Group type: EXPERIMENTAL
Intervention: 100 mg hydrocortisone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 35879804

Group type: EXPERIMENTAL
Intervention: Immediate-release carvedilol-IR
Number of subjects: 0

Group type: COMPARATOR
Intervention: SLOW release carvedilol-SR
Number of subjects: 0
Study: 33844929

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Long Life Family Study (LLFS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FamHS-High Risk
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PRS*FamHS-High Risk
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sex-specific association
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PRS*Sex
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PRS quartile distributions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PRS quartile results
Number of subjects: 8
Study: 33517740

Group type: EXPERIMENTAL
Intervention: Kinematic Alignment (KA)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Mechanical Alignment (MA)
Number of subjects: 138
Study: 34971920

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administration
Number of subjects: 0
Study: 34567787

Group type: EXPERIMENTAL
Intervention: 6 weeks combined centre-based+mHealth home-based CR
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 6 weeks centre-based CR followed by 12 weeks mHealth home-based CR
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 6 weeks combined centre-based+mHealth home-based CR followed by 12 weeks mHealth home-based CR
Number of subjects: 132

Group type: COMPARATOR
Intervention: 6 weeks centre-based CR (standard care)
Number of subjects: 132
Study: 34058256

Group type: EXPERIMENTAL
Intervention: Direct care in Spanish by bilingual physicians
Number of subjects: 83

Group type: COMPARATOR
Intervention: Care through professional interpretive services
Number of subjects: 83
Study: 32081240

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency renal denervation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 51
Study: 34665453

Group type: EXPERIMENTAL
Intervention: Myo-inositol (MI) 4 g/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Metformin (MET) 1500 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both MET and MI
Number of subjects: 66
Study: 34190055

Group type: EXPERIMENTAL
Intervention: Vitamin D (VitD) supplementation
Number of subjects: 161

Group type: COMPARATOR
Intervention: Wnt16 gKO mice with high dosage VitD diet
Number of subjects: 161

Group type: COMPARATOR
Intervention: AIS subjects
Number of subjects: 161
Study: 33333492

Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW) intervention (nFFW = 331)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 667
Study: 35055558

Group type: EXPERIMENTAL
Intervention: Personal low-frequency stimulation (PLS) group (n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Physical therapy group (PTG) (n = 19)
Number of subjects: 39
Study: 32562433

Group type: EXPERIMENTAL
Intervention: Illness representation-focused patient education during hospitalization and telephone follow-ups after discharge
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study: 33478442

Group type: EXPERIMENTAL
Intervention: Adolescents living with perinatal HIV (ALPHIV)
Number of subjects: 707

Group type: COMPARATOR
Intervention: HIV-uninfected adolescents (controls)
Number of subjects: 707
Study: 36336757

Group type: EXPERIMENTAL
Intervention: tDCS (2 mA, 30 min, 22 sessions)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Escitalopram 20 mg/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 34626918

Group type: EXPERIMENTAL
Intervention: Elemental diet (ED) - Elental® 160 g/day
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal diet (Control group)
Number of subjects: 117
Study: 32862174

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 160
Study: 35260152

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle-modification program (10-week-day clinic program)
Number of subjects: 47
Study: 33258297

Group type: EXPERIMENTAL
Intervention: Fused Deposition Modeling (FDM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Digital Light Processing (DLP)
Number of subjects: 20
Study: 34808104

Group type: EXPERIMENTAL
Intervention: Best practice alerts (BPA)
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1310
Study: 34768696

Group type: EXPERIMENTAL
Intervention: Cervical lateral glide (CLG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cervical lateral glide + median nerve neural mobilization (CLG + MNNM)
Number of subjects: 72
Study: 36089597

Group type: EXPERIMENTAL
Intervention: 5% lidocaine patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study: 33737034

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% ophthalmic solution
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 29
Study: 33081739

Group type: EXPERIMENTAL
Intervention: Sankofa pediatric HIV disclosure intervention
Number of subjects: 157
Study: 36017827

Group type: EXPERIMENTAL
Intervention: Multi-day rivastigmine transdermal patch (RID-TDS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Exelon® transdermal patch
Number of subjects: 57
Study: 34541475

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 359
Study: 36309727

Group type: EXPERIMENTAL
Intervention: Fish oil (2.5 grams per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sunflower-seed oil (placebo)
Number of subjects: 70
Study: 32855054

Group type: EXPERIMENTAL
Intervention: Morphine (40 mcg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ketamine (20 mg)
Number of subjects: 80
Study: 34806396

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) - 1 fraction of 15-24 Gy or 3 fractions of 8 Gy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT) - 20 Gy in 5 fractions
Number of subjects: 20
Study: 33317461

Group type: EXPERIMENTAL
Intervention: Arbidol (ARB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: KALETRA (Lopinavir/ritonavir)
Number of subjects: 100
Study: 36081295

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (2 g/day)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo (2 g/day)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 207
Study: 33448755

Group type: COMPARATOR
Intervention: Sham KT and mCIMT group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: KT group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: KT and mCIMT group
Number of subjects: 35
Study: 34669956

Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarettes (2.4% nicotine, n = 118)
Number of subjects: 234

Group type: COMPARATOR
Intervention: No-nicotine e‐cigarettes (n = 116)
Number of subjects: 234
Study: 36858762

Group type: EXPERIMENTAL
Intervention: Text-delivered cognitive behavioral therapy (CBT-txt) with 197 text messages over 4 weeks (average 12 texts every other day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Text-delivered cognitive behavioral therapy (CBT-txt)
Number of subjects: 102
Study: 34344851

Group type: EXPERIMENTAL
Intervention: Lactic acid bacteria‐containing beverage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water
Number of subjects: 40
Study: 33568079

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator (not using telemonitoring)
Number of subjects: 0
Study: 32493442

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham transplantation
Number of subjects: 42
Study: 34415866

Group type: EXPERIMENTAL
Intervention: Standard care augmented by the display of a sepsis early warning system-triggered flag and electronic health record-based pharmacist notification
Number of subjects: 598

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 598
Study: 33805975

Group type: EXPERIMENTAL
Intervention: Novel organic olive oil-based denture adhesive
Number of subjects: 23

Group type: COMPARATOR
Intervention: Commercialized adhesive (control)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vaseline (placebo)
Number of subjects: 23
Study: 32007295

Group type: EXPERIMENTAL
Intervention: U-TURN group (intensive lifestyle intervention with supervised exercise and individualized dietary counseling)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: U-TURN group (intermediate tertile)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: U-TURN group (upper tertile)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: U-TURN group (lower tertile)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 92
Study: 34746999

Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (2 g every 6 hours for 5 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 54
Study: 34774076

Group type: EXPERIMENTAL
Intervention: Blended educational intervention program
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 84
Study: 32816629

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 1050
Study: 35839921

Group type: EXPERIMENTAL
Intervention: Aerobic treadmill rehabilitation (TM; 3 times/wk for 6 months)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Stretching/balance (ST; 2 times/wk for 6 months)
Number of subjects: 246
Study: 33497834

Group type: EXPERIMENTAL
Intervention: Delayed appendectomy (after 6 am)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early appendectomy (within 6 hours of randomization)
Number of subjects: 0
Study: 33175057

Group type: EXPERIMENTAL
Intervention: FunFRIENDS program (Intervention Group, N = 21)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control Group (N = 22)
Number of subjects: 43
Study: 36351512

Group type: EXPERIMENTAL
Intervention: Home meal delivery and provision of cooking/serving resources (MOW cohort, n=83)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Home meal delivery and provision of cooking/serving resources (COM cohort, n=216)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 299
Study: 34166466

Group type: EXPERIMENTAL
Intervention: Burnout prevalence
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Exhaustion
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Disengagement
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Neither exhausted nor disengaged
Number of subjects: 229

Group type: COMPARATOR
Intervention: Association with age, gender, and year of study
Number of subjects: 229
Study: 33539744

Group type: EXPERIMENTAL
Intervention: Carboplatin-based doublet plus bevacizumab (10 mg/kg intravenous every 14 days or 15 mg/kg every 21 days)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Carboplatin-based doublet alone (standard chemotherapy)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Carboplatin-based doublet plus bevacizumab
Number of subjects: 406

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 406
Study: 33009665

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Quarterly and Monthly fremanezumab
Number of subjects: 1890
Study: 32108723

Group type: EXPERIMENTAL
Intervention: Hardwood surface
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Artificial pellet turf
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Grass surface
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Artificial turf
Number of subjects: 38

Group type: COMPARATOR
Intervention: Concrete surface
Number of subjects: 38
Study: 33985942

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg every 4 weeks (Q4W)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 20 mg Q12W (switched to 200 mg at W24)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo Q4W
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 391
Study: 34595963

Group type: EXPERIMENTAL
Intervention: Free From Falls (FFF) group education and exercise program (eight weekly 2 hour sessions)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control condition (a fall prevention brochure and informing their neurologist of their fall history)
Number of subjects: 96
Study: 32972484

Group type: EXPERIMENTAL
Intervention: Community-based nutrition education by trained health volunteers focused on types of locally produced foods and appropriate preparation methods.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Construction of dams at the community level to facilitate all year round farming including rearing of animals.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Provision of agricultural materials such as high yield seedlings, pesticides, and fertiliser.
Number of subjects: 84
Study: 32658647

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35737996

Group type: EXPERIMENTAL
Intervention: Theory-informed educational posters promoting sexual consent
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Theory-informed educational posters promoting sexual consent (for males)
Number of subjects: 40
Study: 34376319

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN) into the MTrP area (10 needle insertions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Dry Needling into the taut band (TB) area)
Number of subjects: 50
Study: 35451678

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg zinc gluconate daily)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 35382377

Group type: EXPERIMENTAL
Intervention: Peer-led education + booklet
Number of subjects: 56

Group type: COMPARATOR
Intervention: Booklet only (control group)
Number of subjects: 56
Study: 33519434

Group type: EXPERIMENTAL
Intervention: Guanxinshutong (GXST) capsules
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 34563627

Group type: EXPERIMENTAL
Intervention: High-dose electro-acupuncture (EA) - seven times each chemotherapy cycle for three cycles
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low-dose electro-acupuncture (EA) - three times each chemotherapy cycle
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: High-dose electro-acupuncture (EA)
Number of subjects: 66
Study: 32950920

Group type: EXPERIMENTAL
Intervention: Small marker (9.5 mm, 1 g)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Large marker (14 mm, 2 g)
Number of subjects: 17
Study: 35875916

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral melatonin 0.5 mg kg ‐1
Number of subjects: 120
Study: 33508735

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) with additional parental coaching
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) without additional parental coaching (active control)
Number of subjects: 22
Study: 35766954

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (ILI) 1.5 mg/kg as a bolus followed by 1.5 mg/kg/h until the end of surgery (Group L)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal saline (Group NL)
Number of subjects: 43
Study: 35005205

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (60 min/session, twice/week for 24 weeks)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study: 36448328

Group type: EXPERIMENTAL
Intervention: Napping 15-59 minutes
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Napping 60+ minutes
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Napping overall
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Nighttime sleep parameters
Number of subjects: 116
Study: 33653204

Group type: EXPERIMENTAL
Intervention: Gameplay (B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined didactic module followed by gameplay (D)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Didactic module (C)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (A)
Number of subjects: 42
Study: 33038262

Group type: EXPERIMENTAL
Intervention: Standard of care plus 12-week intervention (weekly choir rehearsal and daily breathing exercises)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 24
Study: 35443733

Group type: EXPERIMENTAL
Intervention: Moxibustion at Laogong acupoint interval with Panax notoginseng
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (handgrip exercise)
Number of subjects: 74
Study: 35584197

Group type: EXPERIMENTAL
Intervention: AKL-T01 (tablet-based digital treatment)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No contact control
Number of subjects: 60
Study: 34298114

Group type: COMPARATOR
Intervention: Composite (CO)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Glass hybrid (GH)
Number of subjects: 180
Study: 34165095

Group type: EXPERIMENTAL
Intervention: Breastfeeding for 5-10 minutes before immunization
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no breastfeeding)
Number of subjects: 124
Study: 35475684

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 60 billion CFU daily for 4 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) and Placebo
Number of subjects: 81
Study: 34878549

Group type: EXPERIMENTAL
Intervention: Salt substitute (free salt substitute provided)
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Regular salt (control group)
Number of subjects: 1170
Study: 35443143

Group type: EXPERIMENTAL
Intervention: 3-back n-back WM training
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0, 1, 2-back n-back WM training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous attended sensory input
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved WM capacity
Number of subjects: 0
Study: 34155070

Group type: EXPERIMENTAL
Intervention: Guided daily multidisciplinary rounds (DMRs) supported by a remote specialist and audit/feedback on care performance
Number of subjects: 30
Study: 32615109

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-transplantation therapies (control group)
Number of subjects: 45
Study: 34289086

Group type: EXPERIMENTAL
Intervention: Difamilast 0.3%
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Difamilast 1%
Number of subjects: 251

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 251
Study: 33794205

Group type: EXPERIMENTAL
Intervention: Avelumab plus chemoradiotherapy (10 mg/kg avelumab intravenously every 2 weeks plus 100 mg/m2 cisplatin every 3 weeks plus intensity‐modulated radiotherapy with standard fractionation of 70 Gy)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Placebo plus chemoradiotherapy (placebo group)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 697

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 697
Study: 35099133

Group type: EXPERIMENTAL
Intervention: Sublingual Nitroglycerin (NTG) administration
Number of subjects: 77
Study: 32964215

Group type: EXPERIMENTAL
Intervention: Ustekinumab (130 mg intravenous induction, then 90 mg subcutaneous maintenance every 8/12 weeks)
Number of subjects: 2574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2574

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 2574
Study: 35361578

Group type: EXPERIMENTAL
Intervention: CT perfusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dynamic contrast‐enhanced MR imaging
Number of subjects: 24
Study: 34114999

Group type: EXPERIMENTAL
Intervention: Rational emotive education (REE) program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 35218455

Group type: EXPERIMENTAL
Intervention: Arm 1: three consecutive monthly aflibercept injections followed by bimonthly treatment until week 52, then treat-and-extend regimen
Number of subjects: 41

Group type: COMPARATOR
Intervention: Arm 2: treated according to a treat-and-extend protocol throughout the 18-month follow-up
Number of subjects: 41